Shopping Cart 0
Cart Subtotal
USD 0

Ischemia Reperfusion Injury - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Ischemia Reperfusion Injury-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury-Pipeline Review, H2 2018, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.

Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 5, 1, 36 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 20 and 2 molecules, respectively.

Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Ischemia Reperfusion Injury-Overview 6

Ischemia Reperfusion Injury-Therapeutics Development 7

Ischemia Reperfusion Injury-Therapeutics Assessment 19

Ischemia Reperfusion Injury-Companies Involved in Therapeutics Development 29

Ischemia Reperfusion Injury-Drug Profiles 40

Ischemia Reperfusion Injury-Dormant Projects 134

Ischemia Reperfusion Injury-Discontinued Products 139

Ischemia Reperfusion Injury-Product Development Milestones 140

Appendix 144


List Of Figure

List of Figures

Number of Products under Development for Ischemia Reperfusion Injury, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Ischemia Reperfusion Injury, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Ischemia Reperfusion Injury-Pipeline by Akashi Therapeutics Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Angion Biomedica Corp, H2 2018

Ischemia Reperfusion Injury-Pipeline by arGEN-X BV, H2 2018

Ischemia Reperfusion Injury-Pipeline by Balmes Transplantation SAS, H2 2018

Ischemia Reperfusion Injury-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Ischemia Reperfusion Injury-Pipeline by Bolder Biotechnology Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Catalyst Biosciences Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Cellmid Ltd, H2 2018

Ischemia Reperfusion Injury-Pipeline by CFM Pharma Holding BV, H2 2018

Ischemia Reperfusion Injury-Pipeline by Conatus Pharmaceuticals Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Corline Biomedical AB, H2 2018

Ischemia Reperfusion Injury-Pipeline by Gilead Sciences Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Glucox Biotech AB, H2 2018

Ischemia Reperfusion Injury-Pipeline by Hope Pharmaceuticals Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Ischemix Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018

Ischemia Reperfusion Injury-Pipeline by LG Chem Ltd, H2 2018

Ischemia Reperfusion Injury-Pipeline by MallInckrodt Plc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Nissan Chemical Industries Ltd, H2 2018

Ischemia Reperfusion Injury-Pipeline by NovelMed Therapeutics Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Opsona Therapeutics Ltd, H2 2018

Ischemia Reperfusion Injury-Pipeline by Orexo AB, H2 2018

Ischemia Reperfusion Injury-Pipeline by Reata Pharmaceuticals Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by SBI Pharmaceuticals Co Ltd, H2 2018

Ischemia Reperfusion Injury-Dormant Projects, H2 2018

Ischemia Reperfusion Injury-Dormant Projects, H2 2018 (Contd..1), H2 2018

Ischemia Reperfusion Injury-Dormant Projects, H2 2018 (Contd..2), H2 2018

Ischemia Reperfusion Injury-Dormant Projects, H2 2018 (Contd..3), H2 2018

Ischemia Reperfusion Injury-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Ischemia Reperfusion Injury Therapeutic Products under Development, Key Players in Ischemia Reperfusion Injury Therapeutics, Ischemia Reperfusion Injury Pipeline Overview, Ischemia Reperfusion Injury Pipeline, Ischemia Reperfusion Injury Pipeline Assessment


Companies

Akashi Therapeutics Inc

Angion Biomedica Corp

arGEN-X BV

Balmes Transplantation SAS

Boehringer Ingelheim GmbH

Bolder Biotechnology Inc

Catalyst Biosciences Inc

Cellmid Ltd

CFM Pharma Holding BV

Conatus Pharmaceuticals Inc

Corline Biomedical AB

Gilead Sciences Inc

Glucox Biotech AB

Hope Pharmaceuticals Inc

Ischemix Inc

Lee's Pharmaceutical Holdings Ltd

LG Chem Ltd

MallInckrodt Plc

Nissan Chemical Industries Ltd

NovelMed Therapeutics Inc

Opsona Therapeutics Ltd

Orexo AB

Reata Pharmaceuticals Inc

SBI Pharmaceuticals Co Ltd

Ischemia Reperfusion Injury-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury-Pipeline Review, H2 2018, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.

Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 5, 1, 36 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 20 and 2 molecules, respectively.

Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 5

Ischemia Reperfusion Injury-Overview 6

Ischemia Reperfusion Injury-Therapeutics Development 7

Ischemia Reperfusion Injury-Therapeutics Assessment 19

Ischemia Reperfusion Injury-Companies Involved in Therapeutics Development 29

Ischemia Reperfusion Injury-Drug Profiles 40

Ischemia Reperfusion Injury-Dormant Projects 134

Ischemia Reperfusion Injury-Discontinued Products 139

Ischemia Reperfusion Injury-Product Development Milestones 140

Appendix 144


List Of Figure

List of Figures

Number of Products under Development for Ischemia Reperfusion Injury, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Ischemia Reperfusion Injury, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Ischemia Reperfusion Injury-Pipeline by Akashi Therapeutics Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Angion Biomedica Corp, H2 2018

Ischemia Reperfusion Injury-Pipeline by arGEN-X BV, H2 2018

Ischemia Reperfusion Injury-Pipeline by Balmes Transplantation SAS, H2 2018

Ischemia Reperfusion Injury-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Ischemia Reperfusion Injury-Pipeline by Bolder Biotechnology Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Catalyst Biosciences Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Cellmid Ltd, H2 2018

Ischemia Reperfusion Injury-Pipeline by CFM Pharma Holding BV, H2 2018

Ischemia Reperfusion Injury-Pipeline by Conatus Pharmaceuticals Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Corline Biomedical AB, H2 2018

Ischemia Reperfusion Injury-Pipeline by Gilead Sciences Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Glucox Biotech AB, H2 2018

Ischemia Reperfusion Injury-Pipeline by Hope Pharmaceuticals Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Ischemix Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018

Ischemia Reperfusion Injury-Pipeline by LG Chem Ltd, H2 2018

Ischemia Reperfusion Injury-Pipeline by MallInckrodt Plc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Nissan Chemical Industries Ltd, H2 2018

Ischemia Reperfusion Injury-Pipeline by NovelMed Therapeutics Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by Opsona Therapeutics Ltd, H2 2018

Ischemia Reperfusion Injury-Pipeline by Orexo AB, H2 2018

Ischemia Reperfusion Injury-Pipeline by Reata Pharmaceuticals Inc, H2 2018

Ischemia Reperfusion Injury-Pipeline by SBI Pharmaceuticals Co Ltd, H2 2018

Ischemia Reperfusion Injury-Dormant Projects, H2 2018

Ischemia Reperfusion Injury-Dormant Projects, H2 2018 (Contd..1), H2 2018

Ischemia Reperfusion Injury-Dormant Projects, H2 2018 (Contd..2), H2 2018

Ischemia Reperfusion Injury-Dormant Projects, H2 2018 (Contd..3), H2 2018

Ischemia Reperfusion Injury-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Ischemia Reperfusion Injury Therapeutic Products under Development, Key Players in Ischemia Reperfusion Injury Therapeutics, Ischemia Reperfusion Injury Pipeline Overview, Ischemia Reperfusion Injury Pipeline, Ischemia Reperfusion Injury Pipeline Assessment


Companies

Akashi Therapeutics Inc

Angion Biomedica Corp

arGEN-X BV

Balmes Transplantation SAS

Boehringer Ingelheim GmbH

Bolder Biotechnology Inc

Catalyst Biosciences Inc

Cellmid Ltd

CFM Pharma Holding BV

Conatus Pharmaceuticals Inc

Corline Biomedical AB

Gilead Sciences Inc

Glucox Biotech AB

Hope Pharmaceuticals Inc

Ischemix Inc

Lee's Pharmaceutical Holdings Ltd

LG Chem Ltd

MallInckrodt Plc

Nissan Chemical Industries Ltd

NovelMed Therapeutics Inc

Opsona Therapeutics Ltd

Orexo AB

Reata Pharmaceuticals Inc

SBI Pharmaceuticals Co Ltd